According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
MDWD has been the topic of several other reports. Oppenheimer set a $22.00 price target on shares of Par Pacific and gave the company a “buy” rating in a report on Monday, March 25th. ValuEngine cut shares of Virtu Financial from a “hold” rating to a “sell” rating in a report on Tuesday, June 18th.
Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The company had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.60 million. As a group, equities analysts expect that Mediwound will post -0.59 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of the company. Oppenheimer & Co. Inc. grew its holdings in shares of Mediwound by 6.5% during the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 2,000 shares in the last quarter. Meitav Dash Investments Ltd. grew its holdings in shares of Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock valued at $2,993,000 after acquiring an additional 3,536 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 16,840 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock valued at $278,000 after acquiring an additional 17,048 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Mediwound during the 1st quarter valued at $93,000. Institutional investors and hedge funds own 30.78% of the company’s stock.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: Trading Strategy Examples and Plans
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.